110 related articles for article (PubMed ID: 17406606)
1. Preparation of integrin alpha(v)beta3-targeting Ab 38C2 constructs.
Sinha SC; Das S; Li LS; Lerner RA; Barbas CF
Nat Protoc; 2007; 2(2):449-56. PubMed ID: 17406606
[TBL] [Abstract][Full Text] [Related]
2. Multiple catalytic aldolase antibodies suitable for chemical programming.
Goswami RK; Huang ZZ; Forsyth JS; Felding-Habermann B; Sinha SC
Bioorg Med Chem Lett; 2009 Jul; 19(14):3821-4. PubMed ID: 19428247
[TBL] [Abstract][Full Text] [Related]
3. A humanized aldolase antibody for selective chemotherapy and adaptor immunotherapy.
Rader C; Turner JM; Heine A; Shabat D; Sinha SC; Wilson IA; Lerner RA; Barbas CF
J Mol Biol; 2003 Sep; 332(4):889-99. PubMed ID: 12972259
[TBL] [Abstract][Full Text] [Related]
4. Small molecule drug activity in melanoma models may be dramatically enhanced with an antibody effector.
Popkov M; Rader C; Gonzalez B; Sinha SC; Barbas CF
Int J Cancer; 2006 Sep; 119(5):1194-207. PubMed ID: 16570283
[TBL] [Abstract][Full Text] [Related]
5. Beta-lactam-based approach for the chemical programming of aldolase antibody 38C2.
Gavrilyuk JI; Wuellner U; Barbas CF
Bioorg Med Chem Lett; 2009 Mar; 19(5):1421-4. PubMed ID: 19181522
[TBL] [Abstract][Full Text] [Related]
6. Genetic and fluorescence studies of affinity maturation in related antibodies.
Pauyo T; Hilinski GJ; Chiu PT; Hansen DE; Choi YJ; Ratner DI; Shah-Mahoney N; Southern CA; O'Hara PB
Mol Immunol; 2006 Mar; 43(7):812-21. PubMed ID: 16137768
[TBL] [Abstract][Full Text] [Related]
7. Chemical adaptor immunotherapy: design, synthesis, and evaluation of novel integrin-targeting devices.
Li LS; Rader C; Matsushita M; Das S; Barbas CF; Lerner RA; Sinha SC
J Med Chem; 2004 Nov; 47(23):5630-40. PubMed ID: 15509162
[TBL] [Abstract][Full Text] [Related]
8. Enhancing the synthetic utility of aldolase antibody 38C2.
Mondal K; Ramesh NG; Roy I; Gupta MN
Bioorg Med Chem Lett; 2006 Feb; 16(4):807-10. PubMed ID: 16321532
[TBL] [Abstract][Full Text] [Related]
9. Reaction properties of catalytic antibodies encapsulated in organo substituted SiO2 sol-gel materials.
Kato K; Saito T; Seelan S; Tomita M; Yokogawa Y
J Biosci Bioeng; 2005 Oct; 100(4):478-80. PubMed ID: 16310742
[TBL] [Abstract][Full Text] [Related]
10. Visualizing antibody-catalyzed retro-aldol-retro-Michael reactions.
Tanaka F; Kerwin L; Kubitz D; Lerner RA; Barbas CF
Bioorg Med Chem Lett; 2001 Nov; 11(22):2983-6. PubMed ID: 11677141
[TBL] [Abstract][Full Text] [Related]
11. Enantioselective aldol cyclodehydrations catalyzed by antibody 38C2.
List B; Lerner RA; Barbas CF
Org Lett; 1999 Jul; 1(1):59-61. PubMed ID: 10822533
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and evaluation of the aldolase antibody-derived chemical-antibodies targeting α5β1 integrin.
Goswami RK; Liu Y; Liu C; Lerner RA; Sinha SC
Mol Pharm; 2013 Feb; 10(2):538-43. PubMed ID: 23102054
[TBL] [Abstract][Full Text] [Related]
13. Synthesis of the next-generation therapeutic antibodies that combine cell targeting and antibody-catalyzed prodrug activation.
Abraham S; Guo F; Li LS; Rader C; Liu C; Barbas CF; Lerner RA; Sinha SC
Proc Natl Acad Sci U S A; 2007 Mar; 104(13):5584-9. PubMed ID: 17372220
[TBL] [Abstract][Full Text] [Related]
14. Computational elucidation and validation of the three-dimensional structure of humanized aldolase catalytic antibody 38C2.
Jayakody RS; Jasin Arachchige LI; Japahuge A
J Biomol Struct Dyn; 2021 Apr; 39(7):2463-2477. PubMed ID: 32242499
[TBL] [Abstract][Full Text] [Related]
15. Evolution of aldolase antibodies in vitro: correlation of catalytic activity and reaction-based selection.
Tanaka F; Fuller R; Shim H; Lerner RA; Barbas CF
J Mol Biol; 2004 Jan; 335(4):1007-18. PubMed ID: 14698295
[TBL] [Abstract][Full Text] [Related]
16. Chemically Programmed Bispecific Antibody Targeting Legumain Protease and αvβ3 Integrin Mediates Strong Antitumor Effects.
Liu Y; Goswami RK; Liu C; Sinha SC
Mol Pharm; 2015 Jul; 12(7):2544-50. PubMed ID: 26024761
[TBL] [Abstract][Full Text] [Related]
17. Antibody-catalyzed benzoin oxidation as a mechanistic probe for nucleophilic catalysis by an active site lysine.
Sklute G; Oizerowich R; Shulman H; Keinan E
Chemistry; 2004 May; 10(9):2159-65. PubMed ID: 15112204
[TBL] [Abstract][Full Text] [Related]
18. Amperometric assay for aldolase activity: antibody-catalyzed ferrocenylamine formation.
Sagi A; Rishpon J; Shabat D
Anal Chem; 2006 Mar; 78(5):1459-61. PubMed ID: 16503594
[TBL] [Abstract][Full Text] [Related]
19. Breaking the one antibody-one target axiom.
Guo F; Das S; Mueller BM; Barbas CF; Lerner RA; Sinha SC
Proc Natl Acad Sci U S A; 2006 Jul; 103(29):11009-14. PubMed ID: 16822849
[TBL] [Abstract][Full Text] [Related]
20. Synthesis of an organoinsulin molecule that can be activated by antibody catalysis.
Worrall DS; McDunn JE; List B; Reichart D; Hevener A; Gustafson T; Barbas CF; Lerner RA; Olefsky JM
Proc Natl Acad Sci U S A; 2001 Nov; 98(24):13514-8. PubMed ID: 11707596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
